VINC | Vincerx Pharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1800 - 0.2150
52 Week Range	0.1800 - 9.37
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	665,140
Average Volume	671,279
Shares Outstanding	33,650,800
Market Cap	6,969,081
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-05-27

Valuation
Profitability
Growth
Health
P/E Ratio	-0.24
Forward P/E Ratio	N/A
EPS	-0.86
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	42
Country	USA
Website	VINC

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

VINC's peers: APLT, ITRM, MEIP, NCNA, RANI, THTX, TNYA, SPRO, BOLT, CHRS, GRCL, NLTX, LYRA, STTK, BCAB, MNPR, SNTI, PCSA, FRTX, LVTX, TCON, RZLT, XOMA, SIOX, TARA, VCNX, MIRO, SRZN, VIRX

*Chart delayed

Analyzing fundamentals for VINC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see VINC Fundamentals page.

Watching at VINC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VINC Technicals page.